Form 4: Oric Pharmaceuticals Director Exercises Stock Options
SEC Form 4 Filing
Lori Anne Kunkel, a director at Oric Pharmaceuticals, exercised stock options to acquire 20,500 shares of common stock at $3.75 per share on June 3, 2024.
Summary
- On June 3, 2024, Lori Anne Kunkel, a director of Oric Pharmaceuticals, exercised stock options.
- This transaction involved the acquisition of 20,500 shares of common stock at a price of $3.75 per share.
- Following the transaction, Kunkel directly owns 33,200 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of an insider transaction. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it is a standard exercise of stock options by a director.
Key Dates
| Date | Description |
|---|---|
| 06/17/2022 | One thirty-sixth (1/36th) of the remaining 33,200 shares subject to the option shall vest on each monthly anniversary of this date. |
| 06/17/2023 | 20,500 of the shares subject to the option shall vest on the earlier of this date or the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant |
| 06/03/2024 | Date of transaction: Director exercised stock options to acquire 20,500 shares at $3.75. |
| 06/04/2024 | Date of filing of the Form 4. |
| 06/16/2032 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.